These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
838 related items for PubMed ID: 7522959
1. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Cancer Res; 1994 Oct 15; 54(20):5474-8. PubMed ID: 7522959 [Abstract] [Full Text] [Related]
2. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Sadar MD, Gleave ME. Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779 [Abstract] [Full Text] [Related]
3. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J. Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040 [Abstract] [Full Text] [Related]
4. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Murthy S, Agoulnik IU, Weigel NL. Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350 [Abstract] [Full Text] [Related]
5. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1. Zaia A, Fraizer GC, Piantanelli L, Saunders GF. Anticancer Res; 2001 Sep 01; 21(1A):1-10. PubMed ID: 11299720 [Abstract] [Full Text] [Related]
6. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M. Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214 [Abstract] [Full Text] [Related]
7. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Gnanapragasam VJ, Robson CN, Neal DE, Leung HY. Oncogene; 2002 Aug 01; 21(33):5069-80. PubMed ID: 12140757 [Abstract] [Full Text] [Related]
8. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Br J Cancer; 1999 Sep 01; 81(2):242-51. PubMed ID: 10496349 [Abstract] [Full Text] [Related]
9. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z. Cancer Res; 1998 Oct 15; 58(20):4640-5. PubMed ID: 9788616 [Abstract] [Full Text] [Related]
10. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Banham AH, Boddy J, Launchbury R, Han C, Turley H, Malone PR, Harris AL, Fox SB. Prostate; 2007 Jul 01; 67(10):1091-8. PubMed ID: 17477366 [Abstract] [Full Text] [Related]
11. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Uberall F, Klocker H. Cancer Res; 1999 Jan 01; 59(1):227-33. PubMed ID: 9892211 [Abstract] [Full Text] [Related]
12. Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. Henttu P, Vihko P. Cancer Res; 1993 Mar 01; 53(5):1051-8. PubMed ID: 7679946 [Abstract] [Full Text] [Related]
13. Specific block of androgen receptor activity by antisense oligonucleotides. Hamy F, Brondani V, Spoerri R, Rigo S, Stamm C, Klimkait T. Prostate Cancer Prostatic Dis; 2003 Mar 01; 6(1):27-33. PubMed ID: 12664061 [Abstract] [Full Text] [Related]
14. Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Dai J, Shen R, Sumitomo M, Stahl R, Navarro D, Gershengorn MC, Nanus DM. Clin Cancer Res; 2002 Jul 01; 8(7):2399-405. PubMed ID: 12114445 [Abstract] [Full Text] [Related]
15. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. Paliouras M, Diamandis EP. Biol Chem; 2008 Jun 01; 389(6):773-80. PubMed ID: 18627304 [Abstract] [Full Text] [Related]
16. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Oncogene; 2003 Aug 28; 22(36):5602-13. PubMed ID: 12944908 [Abstract] [Full Text] [Related]
18. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Arnold JT, Le H, McFann KK, Blackman MR. Am J Physiol Endocrinol Metab; 2005 Mar 15; 288(3):E573-84. PubMed ID: 15536203 [Abstract] [Full Text] [Related]
19. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA. Mol Cancer Res; 2003 Mar 15; 1(5):385-92. PubMed ID: 12651911 [Abstract] [Full Text] [Related]
20. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Horii K, Suzuki Y, Kondo Y, Akimoto M, Nishimura T, Yamabe Y, Sakaue M, Sano T, Kitagawa T, Himeno S, Imura N, Hara S. Mol Cancer Res; 2007 Apr 15; 5(4):383-91. PubMed ID: 17426252 [Abstract] [Full Text] [Related] Page: [Next] [New Search]